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Novel antibiotic compounds have been prepared through a selective multicomponent
reaction upon the known drug Trimethoprim. The Groebke-Blackburn-Bienaymé reaction
involving this α-aminoazine, with a range of aldehydes and isocyanides afforded the
desired adducts in one-step. The analogs display meaningful structural features of the
initial drug together with relevant modifications at several points, keeping antibiotic
potency and showing satisfactory antimicrobial profile (good activity levels and reduced
growth rates), especially against methicillin-resistant Staphylococcus aureus. The new
products may open new possibilities to fight bacterial infections.
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INTRODUCTION
Trimethoprim (TMP, 1, Figure 1A) is a well-known antibiotic, present in the Model List
of Essential Medicines from the World Health Organization. TMP is usually used in
combinationwith Sulfamethoxazole (SMX) to treat lower urinary tract infections and acute
invasive diarrhea/bacterial dysentery as first and second choice, respectively (WHO, 2017),
respiratory infections in cystic fibrosis patients caused by Staphylococcus aureus, among other
many infections. Lately, it has also been used for preventing infections from the opportunistic
pathogen Pneumocystis carinii (Urbancic et al., 2018), which normally causes pneumonia in
patients with AIDS. Both drugs act on the folic acid biosynthetic route by inhibiting two
enzymes: dihydrofolate reductase (DHFR) and dihydropteroate synthetase, respectively. Folate
needs to be synthesized by bacteria and it is crucial in the biosynthetic pathway of thymidine,
essential in DNA synthesis. Hence, when used in combination, these antibiotics display a
synergistic effect in inhibiting bacterial growth and leading to eventual cell death (Figure 1B)
(Torok et al., 2009; Katzung et al., 2012).
The combination of sulfonamides andDHFR inhibitors has been clinically used since 1968 when
it was first approved in the UK (Cody et al., 2008; Torok et al., 2009). Unfortunately, resistance
emerged soon and has become widespread (Huovinen et al., 1995; Ventola, 2015). Nowadays,
antibiotic resistance is one of the world’s most pressing public health problems with high morbidity
andmortality rates (Centers for Disease Control and Prevention, 2017). Furthermore, finding active
drugs to fight bothmultidrug resistant infections and organisms is becoming extremely challenging,
as is often the case of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant
Pseudomonas aeruginosa. In this context, the co-therapy with TMP and SMX turns out to be
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FIGURE 1 | (A) TMP (1) structure. (B) Folic acid biosynthetic route. (C) Interactions of the TMP (1, in blue) with key amino acid residues at the DHFR binding site.
Representation based on the 2W9H PDB file, with a resolution of 1.48A (Heaslet et al., 2009).
ineffective to treat infections of a subset of bacteria with TMP-
resistant DHFR enzymes (Heaslet et al., 2009).
Thus, the exploration of new synthetic compoundsmimicking
the structure and mechanism of action of conventional
antimicrobial agents can be regarded as a main goal of this field
of research. Such chemical entities would open new perspectives
to reduce secondary effects and to enhance antimicrobial action
and/or spectrum. Moreover, interaction between new molecules
and conventional antimicrobials should be explored with the aim
to find eventual synergistic activity.
So far, some research groups have introduced chemical
variability at the trimethoxybenzyl residue of the TMP in
order to optimize the drug and improve its properties, overall
activity and tackle TMP-resistance issues (Scheme 1) (Zhou
et al., 2013; Lombardo et al., 2016; Rashid et al., 2016),
being able to find promising potent compounds against S.
aureus and E. coli. However, in this work we will focus our
efforts on modifying the 2,4-diaminopyrimidine moiety, through
a selective multicomponent reaction (MCR), the Groebke-
Blackburn-Bienaymé reaction (GBBR). In the past, changes at
this part of themolecule have not been considered, as they involve
key interactions in the recognition of the natural substrate at
the DHFR active site; however, the situation could be otherwise
in mutated enzymes. Furthermore, inspection of the PDB of
the crystal structure of a TMP-DHFR complex shows room for
structural changes at the pyrimidine moiety (Figure 1C) (Heaslet
et al., 2009). These GBBR-type modifications will change the
heterocyclic core of the drug into a more complex di- or tricyclic
azine, and up to four diversity points, which will be introduced
in a regioselective manner (Scheme 1). These transformations,
involving a relevant structural change on the TMP original
framework, strictly speaking cannot be considered as drug late
stage functionalizations (Cernak et al., 2016), although share the
same philosophy of the approach.
MCRs represent an alternative to the usual sequential
multistep synthesis. They involve the reaction of three or more
starting materials in a convergent way to yield an adduct, whose
structure embodies the major part of the reactive materials in a
one-pot reaction through a unified mechanism (Zhu et al., 2014).
Specifically, these reactions bring high efficiency, simplicity and
both atom and step economy. Thus, they are of interest in
medicinal chemistry to assemble relevant, complex heterocycles
with remarkable bioactivities and to speed up the Structure-
Activity Relationship studies (Hulme, 2005; Akritopoulou-Zanze
and Djuric, 2010; Domling et al., 2012; Slobbe et al., 2012;
Zarganes-Tzitzikas and Doemling, 2014).
The GBBR (Scheme 2) is an isocyanide-based MCR yielding
azine-fused imidazoles from readily available aldehydes (2),
isocyanides (3) and amidine-type building blocks (1) (Bienaymé
and Bouzid, 1998; Blackburn et al., 1998; Groebke et al., 1998).
Several reviews have abstracted the main features of this MCR
(Devi et al., 2015; Pericherla et al., 2015). This important
transformation is massively used in medicinal chemistry,
especially in drug discovery, because of the drug like character
of the adduct (imidazo-azine), together with the power to
decorate it with a wide range of structural diversity (Shaaban
and Abdel-Wahab, 2016). These N-fused bicyclic imidazo-azines
represent a special class of privileged scaffold found in several
bioactive compounds and commercially available drugs, such
as Zolpidem, Alpidem, Necopidem, Zolimidine, Divaplon, and
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SCHEME 1 | TMP-GBBR derivatives and precedent modifications on the benzyl moiety.
SCHEME 2 | Mechanism of GBBR.
Minodronic acid (approved for treatments of insomnia, anxiety,
peptic ulcers, epilepsy, osteoporosis, etc.) (Figure 2). It is also
well-known that α-polyamino-polyazines are important aromatic
polyheterocycles present in a wide variety of clinical drugs,
such as the antibacterial drug Trimethoprim, the anticonvulsant
drug Lamotrigine and the anticancer drug Methotrexate.
Furthermore, specific GBBR adducts have been identified as
active antibiotics through phenotypic analyses, addressing a
variety of targets (Al-Tel and Al-Qawasmeh, 2010; Shukla
et al., 2012; Semreen et al., 2013; Kumar et al., 2014). These
facts back our project to modify TMP via GBBR processes to
deliver potentially useful novel antibiotics, either improving the
activity of the original drug upon DHFR or acting through
independent mechanisms.
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FIGURE 2 | Example of commercial drugs with N-fused bicyclic imidazo-azines. The imidazo-azine core is highlighted in bold.
RESULTS AND DISCUSSION
Chemical Synthesis
In this context, we planned to develop a series of TMP derivatives
through the GBBR by interaction of the original drug (TMP, 1)
with a range of aldehydes (2) and isocyanides (3), and analyse
the resultingMCR adducts as novel antibiotics, determining their
potency, and efficiency, also considering their potential impact on
resistant bacteria (Scheme 3).
The chemical modifications on TMP are based in our recent
discoveries on GBBRs upon diaminopyrimidines, involving
selective and multiple MCRs (Ghashghaei et al., 2018). In
this way, the preparation of TMP analogs consisted in a
regioselective mono-GBBR with an aldehyde/isocyanide pair,
to yield derivatives 4; it is worth mentioning that a kinetic
control justifies the preferential formation of the observed
isomer. Furthermore, double GBBR processes upon TMP yield
doubly substituted derivatives 5, with two equivalents of each
reactant class (Scheme 3). The participation of a variety of Lewis
acids catalyst is required to suitably generate and activate the
imine intermediate and to achieve a moderate yield. In addition,
standard flash chromatography purification was normally needed
to afford the pure product. The designed analogs featured the
N-fused bicyclic imidazo-azine scaffolds from the TMP reactant
and displayed the variability points at substituents R1, derived
from the isocyanide input (3) and R2 arising from the aldehyde
reactant (2).
The processes worked in our TMP system as expected,
yielding the corresponding products, showing the same reactivity
and selectivity trends that were described in the unsubstituted
diaminopyrimidine studies (Ghashghaei et al., 2018). For
the initial screening, we prepared a series of TMP analogs
featuring a variety of substituents on the imidazole amino
group (R1, being tert-butyl, 4-methoxyphenyl, cyclohexyl, and
ethoxycarbonylmethyl) whereas at its carbon position a range
of aromatic or alkyl substituents were introduced (R2 being
4-chlorophenyl, α-, β-, or γ-pyridinyl, α-thienyl, methyl, and
isopropyl). All the reactions were successful, yielding the mono-
GBBR derivatives 4 and the doubly substituted-GBBR adducts
5 in acceptable yields (unoptimized). In this way, 12 new
products (4a-4j and 5a-b) arising from the corresponding
aldehyde/isocyanide combinations were suitably prepared as
pure materials (Figure 3).
The connectivity of the first analog synthesized (4a) was
assigned through two-dimensional NMR experiments: HSQC,
HMBC and NOESY spectra (see Supplementary Material)
and matched with the expected structure, displaying the
regioselectivity previously described (Ghashghaei et al., 2018).
The rest of derivatives showed the same spectroscopical trends
and their structures were assigned by analogy. Furthermore, the
doubly substituted GBBR adducts 5 synthetically derived from
the corresponding precursors 4, then securing their identity.
We planned to incorporate an unsubstituted amino group
in the imidazole ring of the novel derivatives 4 and 5 in order
to favor their recognition by the DHFR active site, in line
with the natural substrate. Then, we tackled the preparation
of such compounds through the acidic removal of a tert-butyl
group from a suitable precursor adduct coming from MCRs
involving tert-butyl isocyanide. Precedent work by Krasavin et al.
(2008) demonstrated that this transformation is feasible in GBBR
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SCHEME 3 | Synthesis of mono- (4) and double- (5) TMP GBBR adducts.
FIGURE 3 | TMP mono- (4) and double-GBBR (5) adducts.
adducts. In this way, compounds 6a-6b and 7a were obtained as
pure unsubstituted amino derivatives form tert-butyl precursors
4 and 5, after HBF4 treatment (Scheme 4). All the synthesized
compounds were suitably obtained in pure form, characterized
and forwarded to microbiological analyses.
Biological Analyses
The Minimum Inhibitory Concentration (MIC) values of the
15 TMP analogs against control strains are shown in Table 1
(for details, see the Supplementary Material). Although all the
compounds showed MIC values against E. coli ATCC 25922
and S. aureus ATCC 29213 higher than TMP, some of them
were almost as potent as TMP (4c, 4f, 4h, 4i, 4j and 6a). P.
aeruginosa PAO1 was found to be fully resistant to TMP, as well
as to all new compounds. A preliminary inspection of the results
showed that double GBBR adducts 5 lacked activity, probably
meaning that they were unsuitable for binding to the target sites.
Whereas for derivatives 4 some combinations were unproductive
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SCHEME 4 | (A) Deprotection of N-tert-butyl groups in adducts 4 and 5. (B) TMP-GBBR mono- (6) and double-adducts (7).
(especially the ones with aromatic and acetate R1 substituents
and p-chlorophenyl group at R2 position), those featuring tert-
butyl groups at R1 and isopropyl, methyl, β-, γ- (but not α-)
pyridyl, and α-thienyl groups at R2 were particularly favored.
Moreover, comparing compounds 4d, 4g and 6b, we are able
to confirm that the reduction of R1 substituents size allowed
to decrease the MIC. It is also worthy to emphasize that all
compounds resulted to be more active on E. coli than on S.
aureus; 4i, 4c, and 4f being the most potent ones. Thus, chemical
modifications do not seem to limit the ability of the different
new compounds to penetrate the outer membrane in Gram
negative bacteria.
Almost all the new compounds acted synergistically with SMX
as the control drug TMP did, against E. coli ATCC 25922 and
S. aureus ATCC 29213 (Table 2); the latter species being much
more sensitive to the SMX combination than to the treatment
with the TMP-GBBR analogs alone. It also becomes apparent
that nearly all the new compounds presented high activity against
a set of clinical isolates of MRSA isolated from hospitalized
or Cystic fibrosis (CF) patients. In CF patients, Staphylococcus
aureus (and particularly MRSA) infection is the main challenge
of antibiotic therapy, since the persistent infection caused by
this bacterium is strongly associated with increased rates of
decline in respiratory function and high mortality (Dolce et al.,
2019). Thus, new approaches to fight this kind of bacterium are
mandatory and should be based on new antimicrobials, most
probably combined with conventional ones (Lo et al., 2018;
Xhemali et al., 2019).
Again, derivatives 4c, 4f, 4h, 4i, 4j, and 6b were
the most potent, but interestingly, some adducts which
were not meaningful acting alone (Table 1), on SMX
combination displayed a relevant potency (4a, 4d, 4e,
4g, and 6a). Disappointingly, no effect either of adducts
alone or in combination with SMX was observed on
Pseudomonas aeruginosa in any case, in line with the
detected TMP activity. Particularly interesting are the
activities against MRSA isolates as can be seen in
Table 2, with many derivatives being as active as the
TMP reference.
A relevant feature in the use of an antibiotic is its kinetic
profile. Specifically, a fast reduction of the growth rates of the
infective microorganism is of capital interest in therapeutics,
arguably as important or more than the effective dose. Thus,
the effect of TMP analogs in combination with SMX on the
growth curves of E. coli ATCC 25922 and S. aureus ATCC
29213 was studied for the most interesting compounds (Figure 4
and Supplementary Material). Some differences were observed
at subinhibitory concentrations of the antimicrobials (1/2 MIC
and 1/4 MIC). In both tested bacteria, full inhibition occurred
for derivatives 4g and 4i with SMX (1:20) at 1/2 the MIC
value (Figures 4A,C,D). On the other hand, compounds 4g and
4f, at a concentration of 1/4 MIC, gave similar results than
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TMP at 1/2 MIC against E. coli ATCC 25922 (Figures 4A,B).
In all the cases, significant reductions in the growth rates
were observed when compared with the antimicrobial-free
control, being comparatively better for some conditions than
TABLE 1 | Minimum Inhibitory Concentration (MIC, µM) of TMP and the new





S. aureus ATCC 29213 P. aeruginosa PAO1
TMP 1 0.43 13.78 > 110.22
4a 16.13 > 64.52 > 64.52
4b > 67.01 > 67.01 > 67.01
4c 1.17 18.71 > 74.85
4d 8.19 > 65.50 > 65.50
4e 5.19 > 83.07 > 83.07
4f 1.25 80.10 > 80.10
4g 17.30 > 69.18 > 69.18
4h 2.14 > 68.44 > 68.44
4i 1.02 65.50 > 65.50
4j 2.05 65.50 > 65.50
5a > 45.60 > 45.60 > 45.60
5b > 56.66 > 56.66 > 56.66
6a 4.55 > 72.75 > 72.75
6b 2.46 78.73 > 78.73
7a > 54.29 > 54.29 > 54.29
the TMP reference, especially compound 4i for long culture
times (Figure 4D).
CONCLUSION
The marketed antibiotic TMP (1) has been succesfully modified
by a GBB MCR with a range of commercially available
aldehydes and isocyanides in selective processes yielding mono-
or double- imidazo-azine adducts 4 and 5. A short synthetic
(one or two steps) protocol allowed access to a focused
library of 15 TMP analogs featuring a novel heterocyclic
scaffold with a relevant degree of chemical diversity at
selected positions, including hydrogen atoms, small alkyl groups,
aromatic and heteroaromatic rings. Incidentally, this work
shows the possibility of using known drugs as substrates
for MCRs and, in this manner, opens new ways to develop
novel chemical entities of biological interest from this unusual
origin. Antimicrobial activity of the novel analogs has been
assayed in Grampositive (S. aureus) and Gramnegative (E.
coli) microorganisms as well as on a bacterium considered the
paradigm of resistance (P. aeruginosa). Despite the latter was
resistant to all the new compounds, several mono-adducts 4
displayed MICs in the micromolar range against E. coli and
S. aureus, what make us think that the TMP-derivatives bind
to DHFR as well. The observed impact on growth kinetics
allows us to conclude that the association of these new products
with SMX exert a very similar effect than TMP itself. It is
worthy to emphasize the excellent activities detected against
MRSA strains. Given the reduced size of the focused chemset
analyzed, and the relevant results found, we can conclude that
the novel scaffold synthesized has potential to become a source
for novel antibiotics. Further on going studies along these
TABLE 2 | Minimum Inhibitory Concentration (MIC, µM) of TMP and the new GBBR analogs in combination with Sulfamethoxazole (1:20) against E. coli ATCC 25922, S.
















TMP 1 0.11 0.43 13.78 0.431 0.86 0.22 0.43
4a 2.02 8.06 > 64.52 4.03 8.06 1.01 4.03
4b 67.01 > 67.01 > 67.01 67.01 > 67.01 67.01 > 67.00
4c 1.17 4.68 37.42 4.68 9.36 0.292 1.17
4d 2.05 4.09 > 65.50 4.09 4.093 1.02 4.09
4e 1.30 5.19 > 83.07 1.298 2.60 0.65 1.30
4f 0.63 5.01 40.05 0.63 2.50 0.63 1.25
4g 0.54 4.32 > 69.18 2.16 8.65 1.08 4.32
4h 0.27 2.14 34.22 1.07 1.07 0.27 1.07
4i 0.13 2.05 32.75 0.51 1.02 0.51 1.02
4j 0.26 2.05 32.75 1.02 2.05 0.51 1.02
5a > 45.60 > 45.60 > 45.60 > 45.60 > 45.60 > 45.60 > 45.60
5b 28.33 > 56.66 > 56.66 28.331 > 56.66 14.17 56.66
6a 2.27 9.09 > 72.75 2.27 4.55 1.14 4.55
6b 0.31 2.46 78.73 1.23 2.46 0.62 2.46
7a > 54.29 > 54.29 > 54.29 > 54.9 > 54.29 > 54.29 > 54.29
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FIGURE 4 | Effect of the analogs 4f, 4g, 4i and TMP in combination with sulfamethoxazole (1:20) on the growth curve of E. coli (4g, 4f; A,B) and S. aureus
(4g, 4i; C,D).
lines tackle toxicity, the mechanism of action and bacterial
resistance issues.
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